IBDEI0C8 ; ; 18-NOV-2013
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;NOV 18, 2013
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16304,1,5,0)
 ;;=5^Family H/O Cancer Of Breast
 ;;^UTILITY(U,$J,358.3,16304,2)
 ;;=^295295
 ;;^UTILITY(U,$J,358.3,16305,0)
 ;;=V16.41^^98^883^12
 ;;^UTILITY(U,$J,358.3,16305,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16305,1,4,0)
 ;;=4^V16.41
 ;;^UTILITY(U,$J,358.3,16305,1,5,0)
 ;;=5^Family H/O Cancer Of Ovary
 ;;^UTILITY(U,$J,358.3,16305,2)
 ;;=^317951
 ;;^UTILITY(U,$J,358.3,16306,0)
 ;;=V16.42^^98^883^13
 ;;^UTILITY(U,$J,358.3,16306,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16306,1,4,0)
 ;;=4^V16.42
 ;;^UTILITY(U,$J,358.3,16306,1,5,0)
 ;;=5^Family H/O Cancer Of Prostate
 ;;^UTILITY(U,$J,358.3,16306,2)
 ;;=^317952
 ;;^UTILITY(U,$J,358.3,16307,0)
 ;;=V16.43^^98^883^14
 ;;^UTILITY(U,$J,358.3,16307,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16307,1,4,0)
 ;;=4^V16.43
 ;;^UTILITY(U,$J,358.3,16307,1,5,0)
 ;;=5^Family H/O Cancer Of Testis
 ;;^UTILITY(U,$J,358.3,16307,2)
 ;;=^317953
 ;;^UTILITY(U,$J,358.3,16308,0)
 ;;=V19.5^^98^883^15
 ;;^UTILITY(U,$J,358.3,16308,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16308,1,4,0)
 ;;=4^V19.5
 ;;^UTILITY(U,$J,358.3,16308,1,5,0)
 ;;=5^Family H/O Congenital Anomalies
 ;;^UTILITY(U,$J,358.3,16308,2)
 ;;=^295325
 ;;^UTILITY(U,$J,358.3,16309,0)
 ;;=V19.2^^98^883^16
 ;;^UTILITY(U,$J,358.3,16309,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16309,1,4,0)
 ;;=4^V19.2
 ;;^UTILITY(U,$J,358.3,16309,1,5,0)
 ;;=5^Family H/O Deafness Or Hearing Loss
 ;;^UTILITY(U,$J,358.3,16309,2)
 ;;=^295322
 ;;^UTILITY(U,$J,358.3,16310,0)
 ;;=V17.3^^98^883^18
 ;;^UTILITY(U,$J,358.3,16310,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16310,1,4,0)
 ;;=4^V17.3
 ;;^UTILITY(U,$J,358.3,16310,1,5,0)
 ;;=5^Family H/O Ischemic Heart Dis
 ;;^UTILITY(U,$J,358.3,16310,2)
 ;;=^295305
 ;;^UTILITY(U,$J,358.3,16311,0)
 ;;=V16.6^^98^883^19
 ;;^UTILITY(U,$J,358.3,16311,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16311,1,4,0)
 ;;=4^V16.6
 ;;^UTILITY(U,$J,358.3,16311,1,5,0)
 ;;=5^Family H/O Leukemia
 ;;^UTILITY(U,$J,358.3,16311,2)
 ;;=^295298
 ;;^UTILITY(U,$J,358.3,16312,0)
 ;;=V18.61^^98^883^21
 ;;^UTILITY(U,$J,358.3,16312,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16312,1,4,0)
 ;;=4^V18.61
 ;;^UTILITY(U,$J,358.3,16312,1,5,0)
 ;;=5^Family H/O Polycystic Kidney
 ;;^UTILITY(U,$J,358.3,16312,2)
 ;;=^321531
 ;;^UTILITY(U,$J,358.3,16313,0)
 ;;=V17.0^^98^883^22
 ;;^UTILITY(U,$J,358.3,16313,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16313,1,4,0)
 ;;=4^V17.0
 ;;^UTILITY(U,$J,358.3,16313,1,5,0)
 ;;=5^Family H/O Psychiatric Condition
 ;;^UTILITY(U,$J,358.3,16313,2)
 ;;=^295302
 ;;^UTILITY(U,$J,358.3,16314,0)
 ;;=V19.4^^98^883^23
 ;;^UTILITY(U,$J,358.3,16314,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16314,1,4,0)
 ;;=4^V19.4
 ;;^UTILITY(U,$J,358.3,16314,1,5,0)
 ;;=5^Family H/O Skin Condition
 ;;^UTILITY(U,$J,358.3,16314,2)
 ;;=^295324
 ;;^UTILITY(U,$J,358.3,16315,0)
 ;;=V17.1^^98^883^24
 ;;^UTILITY(U,$J,358.3,16315,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16315,1,4,0)
 ;;=4^V17.1
 ;;^UTILITY(U,$J,358.3,16315,1,5,0)
 ;;=5^Family H/O Stroke (Cerebrovascular)
 ;;^UTILITY(U,$J,358.3,16315,2)
 ;;=^295303
 ;;^UTILITY(U,$J,358.3,16316,0)
 ;;=V16.8^^98^883^20
 ;;^UTILITY(U,$J,358.3,16316,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16316,1,4,0)
 ;;=4^V16.8
 ;;^UTILITY(U,$J,358.3,16316,1,5,0)
 ;;=5^Family H/O Other Specified Cancer
 ;;^UTILITY(U,$J,358.3,16316,2)
 ;;=^295300
 ;;^UTILITY(U,$J,358.3,16317,0)
 ;;=V11.1^^98^883^47
 ;;^UTILITY(U,$J,358.3,16317,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16317,1,4,0)
 ;;=4^V11.1
 ;;^UTILITY(U,$J,358.3,16317,1,5,0)
 ;;=5^Personal H/O Affective Disorder
 ;;^UTILITY(U,$J,358.3,16317,2)
 ;;=^295250
 ;;^UTILITY(U,$J,358.3,16318,0)
 ;;=V15.89^^98^883^55
 ;;^UTILITY(U,$J,358.3,16318,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16318,1,4,0)
 ;;=4^V15.89
 ;;^UTILITY(U,$J,358.3,16318,1,5,0)
 ;;=5^Personal H/O Exposure To Persian Gulf Region
 ;;^UTILITY(U,$J,358.3,16318,2)
 ;;=^295291
 ;;^UTILITY(U,$J,358.3,16319,0)
 ;;=V11.3^^98^883^48
 ;;^UTILITY(U,$J,358.3,16319,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16319,1,4,0)
 ;;=4^V11.3
 ;;^UTILITY(U,$J,358.3,16319,1,5,0)
 ;;=5^Personal H/O Alcoholism
 ;;^UTILITY(U,$J,358.3,16319,2)
 ;;=^295252
 ;;^UTILITY(U,$J,358.3,16320,0)
 ;;=V15.07^^98^883^49
 ;;^UTILITY(U,$J,358.3,16320,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16320,1,4,0)
 ;;=4^V15.07
 ;;^UTILITY(U,$J,358.3,16320,1,5,0)
 ;;=5^Personal H/O Allergy to Latex
 ;;^UTILITY(U,$J,358.3,16320,2)
 ;;=^322043
 ;;^UTILITY(U,$J,358.3,16321,0)
 ;;=V13.4^^98^883^50
 ;;^UTILITY(U,$J,358.3,16321,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16321,1,4,0)
 ;;=4^V13.4
 ;;^UTILITY(U,$J,358.3,16321,1,5,0)
 ;;=5^Personal H/O Arthritis
 ;;^UTILITY(U,$J,358.3,16321,2)
 ;;=^295267
 ;;^UTILITY(U,$J,358.3,16322,0)
 ;;=V12.72^^98^883^51
 ;;^UTILITY(U,$J,358.3,16322,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16322,1,4,0)
 ;;=4^V12.72
 ;;^UTILITY(U,$J,358.3,16322,1,5,0)
 ;;=5^Personal H/O Colon Polyps
 ;;^UTILITY(U,$J,358.3,16322,2)
 ;;=^303401
 ;;^UTILITY(U,$J,358.3,16323,0)
 ;;=V12.59^^98^883^52
 ;;^UTILITY(U,$J,358.3,16323,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16323,1,4,0)
 ;;=4^V12.59
 ;;^UTILITY(U,$J,358.3,16323,1,5,0)
 ;;=5^Personal H/O Congestive Heart Failure
 ;;^UTILITY(U,$J,358.3,16323,2)
 ;;=^303399
 ;;^UTILITY(U,$J,358.3,16324,0)
 ;;=V45.81^^98^883^53
 ;;^UTILITY(U,$J,358.3,16324,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16324,1,4,0)
 ;;=4^V45.81
 ;;^UTILITY(U,$J,358.3,16324,1,5,0)
 ;;=5^Personal H/O Coronary Bypass
 ;;^UTILITY(U,$J,358.3,16324,2)
 ;;=^97129
 ;;^UTILITY(U,$J,358.3,16325,0)
 ;;=V15.84^^98^883^54
 ;;^UTILITY(U,$J,358.3,16325,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16325,1,4,0)
 ;;=4^V15.84
 ;;^UTILITY(U,$J,358.3,16325,1,5,0)
 ;;=5^Personal H/O Exposure To Asbestos
 ;;^UTILITY(U,$J,358.3,16325,2)
 ;;=^303406
 ;;^UTILITY(U,$J,358.3,16326,0)
 ;;=V15.85^^98^883^60
 ;;^UTILITY(U,$J,358.3,16326,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16326,1,4,0)
 ;;=4^V15.85
 ;;^UTILITY(U,$J,358.3,16326,1,5,0)
 ;;=5^Personal H/O Potentially Hazardous Body Fluids
 ;;^UTILITY(U,$J,358.3,16326,2)
 ;;=^303407
 ;;^UTILITY(U,$J,358.3,16327,0)
 ;;=V10.72^^98^883^56
 ;;^UTILITY(U,$J,358.3,16327,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16327,1,4,0)
 ;;=4^V10.72
 ;;^UTILITY(U,$J,358.3,16327,1,5,0)
 ;;=5^Personal H/O Hodgkin's Disease
 ;;^UTILITY(U,$J,358.3,16327,2)
 ;;=^295237
 ;;^UTILITY(U,$J,358.3,16328,0)
 ;;=V15.3^^98^883^57
 ;;^UTILITY(U,$J,358.3,16328,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16328,1,4,0)
 ;;=4^V15.3
 ;;^UTILITY(U,$J,358.3,16328,1,5,0)
 ;;=5^Personal H/O Irradiation
 ;;^UTILITY(U,$J,358.3,16328,2)
 ;;=^295285
 ;;^UTILITY(U,$J,358.3,16329,0)
 ;;=V10.61^^98^883^32
 ;;^UTILITY(U,$J,358.3,16329,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16329,1,4,0)
 ;;=4^V10.61
 ;;^UTILITY(U,$J,358.3,16329,1,5,0)
 ;;=5^Hx Of Lymphoid Leukemia
 ;;^UTILITY(U,$J,358.3,16329,2)
 ;;=Hx of Lymphoid Leukemia^295232
 ;;^UTILITY(U,$J,358.3,16330,0)
 ;;=V12.03^^98^883^33
 ;;^UTILITY(U,$J,358.3,16330,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16330,1,4,0)
 ;;=4^V12.03
 ;;^UTILITY(U,$J,358.3,16330,1,5,0)
 ;;=5^Hx Of Malaria
 ;;^UTILITY(U,$J,358.3,16330,2)
 ;;=Hx of Malaria^303395
 ;;^UTILITY(U,$J,358.3,16331,0)
 ;;=V10.82^^98^883^34
 ;;^UTILITY(U,$J,358.3,16331,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16331,1,4,0)
 ;;=4^V10.82
 ;;^UTILITY(U,$J,358.3,16331,1,5,0)
 ;;=5^Hx Of Malignant Melanoma
 ;;^UTILITY(U,$J,358.3,16331,2)
 ;;=Hx of Malignant Melanoma^295240
 ;;^UTILITY(U,$J,358.3,16332,0)
 ;;=V10.62^^98^883^36
 ;;^UTILITY(U,$J,358.3,16332,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16332,1,4,0)
 ;;=4^V10.62
 ;;^UTILITY(U,$J,358.3,16332,1,5,0)
 ;;=5^Hx Of Myeloid Leukemia
 ;;^UTILITY(U,$J,358.3,16332,2)
 ;;=Hx of Myeloid Leukemia^295233
 ;;^UTILITY(U,$J,358.3,16333,0)
 ;;=V10.63^^98^883^35
 ;;^UTILITY(U,$J,358.3,16333,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16333,1,4,0)
 ;;=4^V10.63
 ;;^UTILITY(U,$J,358.3,16333,1,5,0)
 ;;=5^Hx Of Monocytic Leukemia
 ;;^UTILITY(U,$J,358.3,16333,2)
 ;;=Hx of Monocytic Leukemia^295234
 ;;^UTILITY(U,$J,358.3,16334,0)
 ;;=V11.2^^98^883^30
 ;;^UTILITY(U,$J,358.3,16334,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16334,1,4,0)
 ;;=4^V11.2
 ;;^UTILITY(U,$J,358.3,16334,1,5,0)
 ;;=5^Hx Of Dysthymia
 ;;^UTILITY(U,$J,358.3,16334,2)
 ;;=Hx of Dysthymia^295251
 ;;^UTILITY(U,$J,358.3,16335,0)
 ;;=V15.81^^98^883^46
 ;;^UTILITY(U,$J,358.3,16335,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16335,1,4,0)
 ;;=4^V15.81
 ;;^UTILITY(U,$J,358.3,16335,1,5,0)
 ;;=5^Noncompliance With Medical Treatment
 ;;^UTILITY(U,$J,358.3,16335,2)
 ;;=^295290
 ;;^UTILITY(U,$J,358.3,16336,0)
 ;;=V10.43^^98^883^37
 ;;^UTILITY(U,$J,358.3,16336,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16336,1,4,0)
 ;;=4^V10.43
 ;;^UTILITY(U,$J,358.3,16336,1,5,0)
 ;;=5^Hx Of Ovarian Ca
 ;;^UTILITY(U,$J,358.3,16336,2)
 ;;=Hx of Ovarian CA^295221
 ;;^UTILITY(U,$J,358.3,16337,0)
 ;;=V12.71^^98^883^38
 ;;^UTILITY(U,$J,358.3,16337,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16337,1,4,0)
 ;;=4^V12.71
 ;;^UTILITY(U,$J,358.3,16337,1,5,0)
 ;;=5^Hx Of Peptic Ulcer Disease
 ;;^UTILITY(U,$J,358.3,16337,2)
 ;;=^303400
 ;;^UTILITY(U,$J,358.3,16338,0)
 ;;=V10.46^^98^883^39
 ;;^UTILITY(U,$J,358.3,16338,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16338,1,4,0)
 ;;=4^V10.46
 ;;^UTILITY(U,$J,358.3,16338,1,5,0)
 ;;=5^Hx Of Prostate Cancer
 ;;^UTILITY(U,$J,358.3,16338,2)
 ;;=Hx of Prostate Cancer^295224
 ;;^UTILITY(U,$J,358.3,16339,0)
 ;;=V11.0^^98^883^40
 ;;^UTILITY(U,$J,358.3,16339,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16339,1,4,0)
 ;;=4^V11.0
 ;;^UTILITY(U,$J,358.3,16339,1,5,0)
 ;;=5^Hx Of Schizophrenia
 ;;^UTILITY(U,$J,358.3,16339,2)
 ;;=Hx of Schizophrenia^295249
 ;;^UTILITY(U,$J,358.3,16340,0)
 ;;=V10.83^^98^883^41
 ;;^UTILITY(U,$J,358.3,16340,1,0)
 ;;=^358.31IA^5^2
